Literature DB >> 21168746

Liver transplantation for severe hepatic graft-versus-host disease in two children after hematopoietic stem cell transplantation.

M Teisseyre1, J Teisseyre, P Kalicinski, B Wolska-Kusnierz, H Ismail, E Bernatowska, M Markiewicz-Kijewska, A Ostoja-Chyzynska, I Jankowska, P Kluge, J Pawlowska, M Szymczak.   

Abstract

Chronic graft-versus-host disease (GVHD) is a frequent complication of bone marrow transplantation (BMT). After the skin, the liver is the second, most frequent target of GVHD, which presenting with hyperbilirubinemia, elevated liver enzymes, and coagulopathy. Progressive destruction of small intrahepatic bile ducts causes vanishing bile duct syndrome and leads to end-stage liver disease. We report 2 successful cases of orthotopic liver transplantation performed in children with severe GVHD after hematopoietic stem cell transplantation from a matched unrelated donor (HSCT-MUD).
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21168746     DOI: 10.1016/j.transproceed.2010.09.170

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  Case Report: Liver as a Source of Hematopoietic Stem Cells After Liver Transplantation Following Hematopoietic Stem Cell Transplantation.

Authors:  Tomasz Jarmoliński; Monika Rosa; Blanka Rybka; Renata Ryczan-Krawczyk; Kornelia Gajek; Katarzyna Bogunia-Kubik; Maja Klaudel-Dreszler; Piotr Czubkowski; Piotr Kaliciński; Joanna Teisseyre; Marek Stefanowicz; Ewa Gorczyńska; Krzysztof Kałwak; Marek Ussowicz
Journal:  Front Pediatr       Date:  2022-03-23       Impact factor: 3.418

2.  Treatment with Apocynin Limits the Development of Acute Graft-versus-Host Disease in Mice.

Authors:  Barbara Maximino Rezende; Priscila T T Bernardes; William Antonio Gonçalves; Carolina Braga de Resende; Rayssa Maciel Athayde; Thiago Vinicius Ávila; Débora Gonzaga Martins; Marina G M Castor; Mauro M Teixeira; Vanessa Pinho
Journal:  J Immunol Res       Date:  2019-11-03       Impact factor: 4.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.